We would love to hear your thoughts about our site and services, please take our survey here.
Seriously though re Touchlight do have a look at their website, facilities and experrtise. Brilliant story and an ongoing success. Sadly not available for investment but fascinating.
At Touchlight, we are disrupting the decades-old technology of DNA manufacture to advance genetic medicine. We have developed a novel, synthetic DNA vector, known as doggybone DNA or dbDNA™ and enzymatic manufacturing process, which enables us to produce DNA at unprecedented speed, scale and purity.
For dogbone dna look at the private company Touchlight based at Hampton/sunbury. https://www.touchlight.com/platform-technology/overview/?utm_term=synthetic%20dna%20companies&utm_campaign=Lead+generation&utm_source=adwords&utm_medium=ppc&hsa_acc=4881064295&hsa_cam=14959054942&hsa_grp=128116580523&hsa_ad=553255385934&hsa_src=g&hsa_tgt=kwd-303253519603&hsa_kw=synthetic%20dna%20companies&hsa_mt=b&hsa_net=adwords&hsa_ver=3&gad=1&gclid=CjwKCAjwgZCoBhBnEiwAz35RwrrFlmDCQKvfj9ls0AAgyx5pUD_eRpvVIlHBbd0klofGhWctXWgdghoCc9gQAvD_BwE
Easy there. Enjoy the rns and a coffee……
Wondering about that US commercial office near Astra Zenica offices….
Not 6th but Friday 8th…..my error….runs 5-8. Link still good and they are in impressive company!
Https://world-cdx.com/whats-on/agenda/day-two/
3:00 pm 3D Genomic Liquid Biopsy: Predictive, Prognostic and Diagnostic Biomarkers; from immuno-oncology to early screening of populations at risk
Alexandre Akoulitchev
Chief Scientific Officer, Oxford BioDynamics plc
Synopsis
EpiSwitch® 3D Genomic blood-based platform: from fundamental epigenetic biology to systemic clinical biomarkers for disease diagnosis, prognosis and prediction of treatment response;
EpiSwitch CiRT (Checkpoint Inhibitor Response Test): Highly sensitive clinical blood test for prediction of systemic response to PD-1/-L1 immune checkpoint inhibitors;
EpiSwitch PSE (Prostate Screening Test): novel, highly accurate, multivariant clinical blood test combining PSA with EpiSwitch biomarkers for a breakthrough in prostate cancer screening
Preceding session….astra zenica et al on diagnostics and biomarkers
Nice little mention inside weekend FT money section, top of page 2. No link as I am a paperbased weekend reader. Highlights unique if early stage nature of project. GLA
Likewise expected more….. but no one is looking. Not even the Vulpes followers seem to have noticed the Diggle trades in April…..need a bit of profile raising but I am equally happy to wait for next stage delivery rather than speculaton.
Nice spot indeed and correct interpretation. Please post more if found. Not one of my first languages but I can read Portuguese
Just had a quick listen , rough summary only. So they start with a poll of whether fin tech will make a difference - comes out with yes because it is innovation (as opposed to option 2 yes if it actually makes a difference) . Moving on to business they are initially talking about the idea that fintec in the past has been about process improvement in big banks with legacy systems and often focused around improvement of the user experience. This is not the same as product innovation. AZ launches into SYME around 9.39 telling the historic syme story as one of product not process innovation. At 12:04 he explains the model. There are giggles as he is explaining the process around the monetisation of parmigiano reggiano , but the idea is that this is not a financing but a securitisation, a monetisation of inventory which gains in value as it progresses towards sale / in time (envecchimento - ageing) . This is important as later he ends with reference to why this is a product innovation for the shariah world - not a financing but a monetisation of inventory. Around 16 very interesting as he discusses with what I read as disguised frustration and a desire to get this message out there that have been complications produced by not only being an innovator, but a quoted innovator, which has required them to have what he calls a "pitstop" whereby the regulatory authorities wanted to be assured that what was being publicised under market rules was effectively true. Goes round this point a few times. References also to covid delaying this here, but positive outcomes on discussions with regulatory bodies overseas which now understand our (Italian derived) model. Moves on to referring back to the Italian bank model which is to evidence the product innovation, and the interest this has awoken in the shariah world. Reference also to the importance of the Tradecapital purchase with a 3 year trading record. Also to the importance of monetising the entire product chain to help through trade issues such as Covid and recent Suez. Underlying theme Italy millions are a demonstration, the market is billions . Sorry quick summary - worth trying to go through. I read him as playing a very straight bat, and wanting to pass on the message of robust and steady management rather than start up "froth". Hope this helps, don't shoot the messenger.
https://us02web.zoom.us/webinar/register/WN_DCpwJH6iTC-UG208DshGrg
Registration for results webinar
Report in portuguese press re local protests during August. Confirms known timetable of consultation closed last month and outcome due 3 months. Will be more news from protest side mid August. Will keep an eye.
https://www.tsf.pt/portugal/sociedade/protesto-contra-as-minas-no-barroso-com-tratores-caminhadas-e-acampada-14002093.html
Final results last year 19 August.....not heard re this year. Upcoming financial calendar blank on company website. .....
Nice to see Sebastian Marr on board.....watching with interest now.
Interesting... monecor london aka etx capital. Wonder what they are after.....
https://twitter.com/stockboxmedia/status/1381974536506249217?s=12
Look at the price targets within the incentivisation
We had a trading update 30th march last year. You can scroll back via rns feed to see how it looked but could well get similar shortly.